tbuckley/cabot-search huggingface dataset:
National survey of breast cancer screening in rural America.
Authors: Jeffrey M. Peppercorn, Kevin Houck, Adane Fekadu Wogu, Victor Villagra, Gary H. Lyman, Stephanie B. Wheeler
Journal: Journal of Clinical Oncology (2013)

13 Background: Screening mammography leads to early detection of breast cancer and improved survival. We conducted a survey of predominantly rural U.S. women who receive health insurance through the National Rural Electric Cooperative Association (NRECA) to evaluate the prevalence of annual and biennial screening and to identify potential disparities and barriers to breast cancer screening. Methods: We conducted a national cross-sectional survey of women between ages 40 and 65 who are insured by the NRECA regarding their utilization of mammography screening and barriers to screening. A study specific survey was mailed to 2,000 randomly selected eligible women without prior diagnosis of breast cancer. We assessed demographics and receipt of mammography within past 12 months (all women) and number of screening mammograms within the past 4 years (among women age 44 and older) to identify consistent annual screening and biennial screening patterns. Results: 1,204 women responded to the survey (response rate 60.2%). 74% live in rural areas, 18% suburban, 8% urban. 73% report less than 4 years college education and 19% have family incomes &lt; $50,000/year. Overall, 72% reported screening mammography within 12 months, 59% reported consistent annual screening and 84% reported at least biennial screening. Rural women were less likely to undergo consistent annual (56% vs. 66%, p = 0.003) or biennial screening (82% vs. 89%, p = 0.01) compared to women in non-rural areas. Women under 50 were less likely to report screening within 12 months (67% vs. 77%, p = 0.0002), consistent annual (49% vs. 63%, p &lt; 0.0001) or biennial screening (79% vs. 86%, p = 0.002). Significantly more rural women cited cost and distance as barriers, while busy schedule, fear of diagnosis, and fear of discomfort were important barriers among all demographic groups. Fear of the test was a greater barrier among younger vs. older women (p &lt; 0.02). In univariate analysis; household income did not correlate with screening, and education was only a factor among younger women. Conclusions: A substantial percentage of rural U.S. women fail to undergo screening mammography. Potentially modifiable barriers include out of pocket expenses, convenience of screening, and fear of diagnosis and the test itself.
"Leukocyte Emigrating Factor" of the Mouse Uterus
Authors: D L BEAVER, E S DUMMIT
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sexual histories and premenstrual affective syndrome in psychiatric inpatients
Authors: R C Friedman, S W Hurt, J Clarkin, R Corn, M S Aronoff
Journal: American Journal of Psychiatry (1982)

Of 45 female inpatients with schizophrenia, depression, borderline personality, or depression and borderline personality, 28 met criteria for probable or definite premenstrual affective syndrome. Of these 28, 16 had abnormal sexual histories, compared with only 1 of the 17 women who did not have premenstrual affective syndrome. Of the 12 patients with both depression and borderline personality disorder, 9 had both premenstrual affective syndrome and abnormal sexual histories. The 6 patients who had been raped all met the criteria for premenstrual affective syndrome. The authors suggest that premenstrual affective syndrome may signify unresolved sexual conflicts in subgroups of psychiatric patients.
The curandero's apprentice: a therapeutic integration of folk and medical healing
Authors: J J Kreisman
Journal: American Journal of Psychiatry (1975)

The author discusses alternative methods for dealing with folk illness in psychotherapy. Two case reports are presented that describe psychotic Mexican-American patients who were successfully treated with an approach that integrated curanderismo, the Hispanic concept of healing, and traditional therapy. The author discusses ethical aspects of this integrated approach and suggests that cultural considerations can be successfully incorporated into a treatment plan of optimum benefit for the individual patient.
Prenatal Antidepressant Use and Risk of Autism Spectrum Disorders in Children
Authors: Keith Fluegge
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
PARE0010 Alkaptonuria: An Old Disorder with a Late Diagnosis
Authors: S. Sestini, L. Millucci, D. Braconi, G. Bernardini, A. Santucci
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Alkaptonuria (AKU) is the first genetic metabolic disorder following an autosomal recessive pattern of inheritance, identified by Sir Achibald Edward Garrod (1). It is caused by a mutation in the <i>HGD</i> gene coding for the enzyme homogentisate 1,2-dioxygenase (E.C:1.13.11.5). The natural substrate of the enzyme, the homogentisic acid, is then accumulated in the blood and tissues, oxidated in a form called alkapton and then partially excreted in the urine, giving it an unusually dark color after it is exposed to the air. The excess of homogentisic acid causes damages to connective tissues with dramatic consequences as osteoarthritis and heart valves problems, with subsequent joint and valves replacement, stones in kidney and other organs are affected too. Usually symptoms develop in people after the third decade of age, and this make the disorder undervalued even though the dark discoloration of the urine is present from birth. AKU is a very rare disease, since its prevalence is 1-9/1 000 000 (Orphanet) and, at the moment, without a definite cure. <h3>Objectives</h3> To evaluate the age at which AKU patients have been diagnosed, since on the basis of our experience the highest number of the adults received the exact diagnosis of AKU only late in age, after a long way looking for a resolution of their pain problems. <h3>Methods</h3> To evaluate the age at which AKU patients have been diagnosed, since on the basis of our experience the highest number of the adults received the exact diagnosis of AKU only late in age, after a long way looking for a resolution of their pain problems. <h3>Results</h3> The mean age of the patient was 50.1±17.3. Only 5 of them were diagnosed at the birth, the majority of the others (15) received the diagnosis between 40 and 58 years. The earliest diagnosis dates back to 1971, and in total 11 patients were diagnosed up to 1996, while 13 of them were diagnosed between 2004 and 2014. Apart from the mother9s curiosity about the darkness of nappies which, however, did not always lead to a quick resolution, the physical difficulties leading patients to the diagnosis were different, but often due to rheumatic and orthopedic problems (back pain, arthroscopy, junction replacement, etc). <h3>Conclusions</h3> Although the age of the diagnosis is decreased in the new century, too many people suffer without knowing to be affected by AKU. We hope the rheumatologists will play attention in considering AKU in their diagnosis and share the information with their colleagues like pediatricians, orthopedists, etc. <h3>References</h3> A.B. Garrod The Incidence of Alkaptonuria: a Study in Chemical Individuality Lancet, vol ii, pag. 1616-1620, 1902. <h3>Disclosure of Interest</h3> None declared
A longitudinal study characterising a large adult primary ciliary dyskinesia population
Authors: Anand Shah, Amelia Shoemark, Stephanie J. MacNeill, Basrull Bhaludin, Andrew Rogers, Diana Bilton, David M. Hansell, Robert Wilson, Michael R. Loebinger
Journal: European Respiratory Journal (2016)

Primary ciliary dyskinesia (PCD) in adults has not been well described. In this retrospective observational study we aimed to characterise a large adult population and identify features associated with disease progression. We retrospectively analysed 151 adult patients at a single tertiary centre at baseline and longitudinally for a median of 7 years. We found significant variation in age at diagnosis (median 23.5 years; range &lt;1–72 years). Older age at diagnosis was associated with impaired baseline forced expiratory volume in 1 s (FEV 1 ) (r= −0.30, p=0.01) and increased Pseudomonas aeruginosa colonisation (difference in medians 17 years (95% CI 4.5–20 years); p=0.002). Lung function decline was estimated at FEV 1 decline of 0.49% predicted per year. Lung function decline was associated with ciliary ultrastructure, with microtubular defect patients having the greatest decline (p=0.04). High-resolution computed tomography (HRCT) scores of severity of bronchial wall dilatation (p&lt;0.001) and extent of bronchiectasis (p=0.03) additionally showed evidence of modifying FEV 1 decline with age. Our study reveals that a large proportion of adult PCD patients are diagnosed late, with impaired FEV 1 and increased P. aeruginosa colonisation. Increased disease burden on HRCT and ciliary ultrastructure may predict progressive lung function decline. This study characterises a large adult PCD population, identifies features associated with disease progression and highlights the need for prospective trials to determine whether early diagnosis of high-risk subgroups alongside optimal management can modify disease progression.
AB0597 Sjogrenser Cohort: Clinical and Epidemiological Features of Primary SjÖgren's Syndrome in Spanish Rheumathology Departments
Authors: M. Fernandez Castro, J.L. Andreu, V. Martínez Taboada, A. Olivé, J. Rosas, C. Sánchez-Piedra, R. Menor, B. Rodriguez, A. García Aparicio, F.J. Lόpez Longo, S. Manrique-Arija, J.A. García Vadillo, S. Gil Barato, R. Lόpez González, F.J. Narváez, C. Galisteo, J. González Martín, E. Ruiz Lucea, A. Naranjo, O. Illera
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Primary Sjögren syndrome (pSS) is a systemic autoimmune disease affecting primarily the exocrine glandular system that requires a multidisciplinary approach. <h3>Objectives</h3> The aim of our study was to describe the clinical and epidemiological features of a pSS9s cohort of patients visited in Spanish Reumathology Departments <h3>Methods</h3> This is a multicenter descriptive transversal study of pSS patients fulfilling European/American consensus criteria from thirty three Rheumatology departments. Patients were included by randomisati from an anonymized list provided by every department. Data were collected by reviewing clinical records and an interviewing the patients. Informed consent was obtained and local ethics committees approved the study. Variables were analysed by descriptive statistical methods, using means, medians, and rates, with their deviations and interquartile ranges (p25-p75). <h3>Results</h3> Four hundred and thirtyseven patients were included. Ninety five percent of them were women, with a median age of 58. Eighteen percent of the patients had a familiar history of autoimmune disease, most commonly rheumatoid arthritis. Median age at the time of the first symptoms was 46 years and at pSS9s diagnosis was 50 years. Ocular symptoms (94%) were the most frequent complaint, followed by mouth dryness (94%), and ocular foreign body sensation (92%). Schirmer9s test was performed in 402 patients and was positive in 85% of the cases. Basal salivary flow test was performed in 133 patients, and 89% were positive. Rose Bengal staining test was performed in 144 patients and was positive in 81 percent of them. Salivary gland scintigraphy was performed in more than fifty percent of patients and 87% showed abnormal results. Salivary gland biopsy was obtained in 193 patients, fulfilling histological criteria in 69% of them. Anti-Ro/SS-A, in 93% of the cases, and anti-La/SS-B, in 67%, were found positive during follow up. Only 27% of the patients fulfilled the new 2012 SICCA-ACR classification criteria. <h3>Conclusions</h3> The clinical and demographical profile of pSS patients from Spanish rheumatology departments is similar to that previously described in other series. Diagnostic delay is substantial. A majority of patients showed ocular and oral symptoms. Schirmer test was the preferred diagnostic test used for dry eye evaluation. Only a small group of patients fulfilled the new 2012 ACR classification criteria. <h3>Disclosure of Interest</h3> None declared
The future of cancer research and the role of the National Cancer Institute.
Authors: R D Klausner
Journal: Journal of Clinical Oncology (1996)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.10.2878 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8874348 The future of cancer research and the role of the National Cancer Institute. R D KlausnerxR D KlausnerSearch for articles by this author Show More National Cancer Institute, Bethesda, MD 20892, USA. https://doi.org/10.1200/JCO.1996.14.10.2878 First Page PDF © 1996 by American Society of Clinical Oncology
Notice of Retraction: Sato Y, et al. The Prevention of Hip Fracture With Risedronate and Ergocalciferol Plus Calcium Supplementation in Elderly Women With Alzheimer Disease: A Randomized Controlled Trial. Arch Intern Med. 2005;165(15):1737-1742.
Authors: Howard Bauchner, Rita F. Redberg
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Trazodone for antidepressant-associated insomnia
Authors: A A Nierenberg, L A Adler, E Peselow, G Zornberg, M Rosenthal
Journal: American Journal of Psychiatry (1994)

The authors investigated trazodone as a hypnotic for depressed patients who had persistent, exacerbated, or new insomnia while taking either fluoxetine or bupropion.Seventeen depressed patients who had insomnia while taking fluoxetine or bupropion were given either trazodone or placebo in a double-blind crossover trial. Sleep was assessed by self-report with the Pittsburgh Sleep Quality Index and the sleep items of the Yale-New Haven Hospital Depressive Symptom Inventory.Improvement with trazodone, but not with placebo, was shown by the total Pittsburgh index scores and Yale-New Haven inventory total sleep scores and by the Pittsburgh index measures of sleep duration and Yale-New Haven inventory measures of early morning awakening, and there was a trend toward improvement in the Yale-New Haven inventory item regarding middle of the night awakenings. Subjective sleep quality and sleep latency also showed a trend toward improvement, but the Pittsburgh index measures of sleep efficiency and disturbances and the Yale-New Haven inventory item regarding difficulty falling asleep were unaffected by trazodone. One patient dropped out because of excessive daytime sedation with trazodone, and another dropped out because of nonresponse to placebo. Of the completers, 67% experienced overall improvement in sleep with trazodone according to a priori criteria, whereas only 13% experienced improvement with placebo.Trazodone is an effective hypnotic for patients with antidepressant-associated insomnia.
A naturalistic study of imipramine in panic disorder and agoraphobia
Authors: T A Aronson
Journal: American Journal of Psychiatry (1987)

This naturalistic study examined the treatment response to imipramine of 60 patients who had panic disorder or agoraphobia with panic attacks. Only half of the patients could tolerate the drug, but of those who did, 88% obtained a markedly beneficial clinical effect. An amphetamine-like side effect accounted for most of the dropouts. More than one-half of the responders achieved clinical remission at doses (less than or equal to 100 mg/day) and plasma levels (less than or equal to 150 ng/ml) considered to be subtherapeutic for depression. There appears to be neither a clear threshold for response nor a therapeutic dose range for imipramine in the treatment of panic. Doses should be adjusted individually and increased conservatively.
SAT0489 Disease Activity and Health Status in a Cohort of Young Adults with JIA
Authors: M. Romano, A. Salmaso, S. Lodi-Rizzini, M. Gattinara, I. Pontikaki, P.L. Meroni, V. Gerloni
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Juvenile Idiopathic Arthritis (JIA) is the most prevalent chronic rheumatic disease in childhood. Disease activity can persist for many years, even through adulthood. <h3>Objectives</h3> To evaluate disease activity and health status in a cohort of young adults with JIA. <h3>Methods</h3> In order to identify patients with persistent active disease or in Clinical Remission off medication (CR) according to Wallace criteria all young people (over 18 year old), followed in our Transitional Care Clinic, were assessed by clinical examination [including registration of number of joints with swelling, tenderness and limited range of motion (LROM), number of active joints] and laboratory parameters. Physician9s global assessment of disease activity measured on a 10 cm VAS, Quality of life according to the Medical Outcome Study 36-item Short Form Health Survey (SF-36), physical disability and discomfort by the Health Assessment Questionnaire (HAQ) were also recorded. <h3>Results</h3> 335 consecutive JIA pts (F 237) were evaluated: 39 (11.6%) systemic arthritis, 117 (34.9%) persistent oligoarticular, 48 (14.3%) extended oligoarticular, 80 (23.8%) polyarticular JIA (21 were RF positive), 37 ERA (11%), 14 psoriasic JIA (4.1%). Median age at disease onset was 7.0 yrs (mean 7.8, range 0.1-16.0). Median disease duration was 21.9 yrs (mean 22.7, range 7-51). 237/335 pts were on antirheumatic medication: 134 with biological therapy (BT), 167 with one or more DMARDs and 125 with NSAIDs. Out of the 134 treated with BT 90 were also treated with one or more DMARDs. 98 pts were off medication: 66 of them (67.3%) were inactive and 73 had physician9s VAS &lt;1 cm. In total 40.2% (135/335) presented active joints, ranging from 48.6% (12/39) systemic JIA to 28.5% (4/14) psoriasic JIA. All 335 pts received also SF-36 physical score (median 56, mean 62, range 1-99) and SF-36 mental score (median 61, mean 623, range 12-100). In total 149 pts (44.4%) had a pathological HAQ ranging from 69.2% of systemic onset JIA (median 0.625, mean 0.8, range 0-3) to 29% of persistent oligoarticular JIA (median 0.0, mean 0.2, range 0-1.6). <h3>Conclusions</h3> Our results support that a substantial proportion of the young adults with JIA had an active disease or was on CRM (still needing antirheumatic therapy) and patient-reported health status was not completely satisfactory in a significant number of them. These results suggest that JIA is not a self-limiting disease and therefore ideally all young pts should be followed by both pediatric and adult rheumatology as a part of a transitional care program. <h3>References</h3> Selvaag AM, et al. Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis. Ann Rheum Dis 2014;0:1-6. <h3>Disclosure of Interest</h3> None declared